Highest-materiality recent filing
Nasdaq notified HeartSciences on Aug 4, 2026 of non-compliance with Rule 5550(b)(1) requiring $2.5M stockholders' equity.
HeartSciences files proxy for Fortitude Mining all-stock merger; FY2026 cash $1.7M, no revenue
Filed preliminary proxy for all-stock merger with Fortitude Mining; ~107.6M shares to DCG, pro forma equity $70M.
HeartSciences files 8-K/A with Fortitude Mining financials for pending merger
Amendment provides audited Fortitude financials for years ended Dec 31, 2025 (revenue $89.5M, net loss $12.7M) and 2024 (revenue $81.8M, net loss $14.4M).
HeartSciences Amends Merger Agreement with Fortitude Mining Holdings
Amendment No. 1 to Merger Agreement dated July 27, 2026, among HeartSciences, Fortitude Mining Holdings, Fortitude Mining HoldCo, and Cordis Acquisition.
HeartSciences enters merger agreement with Fortitude Mining and amends CFO terms
HeartSciences entered a Merger Agreement with Fortitude Mining Holdings on June 23, 2026, to acquire Fortitude Mining HoldCo.
HeartSciences signs merger with Fortitude Mining; new CEO and CFO named
Agreement and Plan of Merger with Fortitude Mining Holdings, Fortitude Mining HoldCo and Cordis Acquisition; closing subject to conditions.
HeartSciences enters all-stock merger agreement with Fortitude Mining; combined co to trade as TUDE
Definitive all-stock merger: HeartSciences to combine with Fortitude Mining Holdings; combined entity to operate as Fortitude.
HeartSciences to acquire Fortitude Mining; Fortitude holders to own ~95% of combined entity
Merger with Fortitude Mining (Zcash mining, owned by Digital Currency Group) signed; closing expected H2 2026.
HeartSciences COO and Board Member Mark Hilz passes away at 67
Mark Hilz, COO, Corporate Secretary and Board member, died April 1, 2026 after an illness.
HeartSciences issues $3.6M 12% promissory note to Streeterville Capital, netting $3M
Company entered Note Purchase Agreement with Streeterville Capital for $3,605,000 promissory note, netting $3,000,000 after $600,000 OID and $5,000 expenses.
Board approved Amendment No. 3 to 2023 Equity Incentive Plan, increasing authorized shares from 1M to 1.25M plus annual evergreen.
HeartSciences extends loan maturity to 2026, raises $6.7M in Reg A, exchanges $2.06M debt for equity
Loan maturity extended to Sept 30, 2026; accrued interest payment structure amended.
HeartSciences regains Nasdaq minimum equity compliance; delisting risk cleared
Received formal notice on Sept 16, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform
No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
HeartSciences raises $5.4M in Reg A offering, exchanges $1.8M debt for shares
Received $5.4M gross proceeds from Reg A offering of units at $3.50; 1,556,409 units issued as of Sep 5, 2025.
HeartSciences raises $5.2M in Reg A offering and exchanges $1.655M debt for equity
Gross proceeds of $5.2M from offering of 1,484,440 Units at $3.50/Unit as of Aug 22, 2025.
HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform
Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.
FDA granted Breakthrough Device designation for HeartSciences' Aortic Stenosis AI-ECG algorithm.
Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M
Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
HeartSciences receives Nasdaq delisting notice over $1.79M equity vs $2.5M minimum
Received Nasdaq deficiency letter on March 19, 2025: stockholders' equity of $1.79M below $2.5M minimum.
HeartSciences Q3 FY2025 no revenue, cash $2.6M; FDA submission for MyoVista device expected H1 2025
No revenue for Q3 FY2025; cash and equivalents $2.6M, shareholders' equity $1.8M as of Jan 31, 2025.
HeartSciences withdraws S-1 registration statement for proposed public offering
Withdrew Registration Statement on Form S-1 filed June 7, 2023 (as amended).
Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
Issued $2.51M unsecured promissory note to Streeterville Capital; 8.5% interest, 18-month maturity, $500K OID.
HeartSciences regains Nasdaq minimum bid price compliance; hearing cancelled
Nasdaq notified HeartSciences on June 3, 2024 that it regained compliance with $1.00 minimum bid price requirement.
Heart Test Labs obtains temporary stay of Nasdaq delisting; hearing set for June 27
Nasdaq delisting action stayed pending oral hearing on June 27, 2024.
Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments
Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.
Heart Test Laboratories to effect 1-for-100 reverse stock split on May 17, 2024
Reverse stock split of common stock and warrants at 1-for-100 ratio, effective at market open on May 17, 2024.
Received Nasdaq staff determination to delist under Low Priced Stocks Rule (closing bid ≤$0.10 for 10 consecutive days).
HeartSciences Q3 cash $7.1M; licenses AI-ECG from Mount Sinai; FDA 510(k) path
No significant revenue in Q3 FY2024; cash $7.1M, shareholders' equity $8.6M as of Jan 31, 2024.
Effective December 27, 2022, Patrick Kanouff voluntarily resigned from the Board of Directors (the “Board”) of Heart Test Laboratories, Inc. (the “Company”).
Effective December 28, 2022, the Board appointed David R. Wells to the Board as a director to fill the vacancy created by Mr. Kanouff’s resignation.
Max materiality 0.95 · Median 0.60 · Most common event other_material